B-cell lymphoma-2 inhibition and resistance in acute myeloid leukemia

doi:10.5306/wjco.v11.i8.528

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6349)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

360

WORD

197

HTML

2710

Figures (1-1)

248

Tables (1-1)

259

Sum=3774

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

384

Download

669

Sum=1053

Publishing Process of This Article

Item

Count

Browse

567

Download

955

Sum=1522

Aug 24, 2020 (publication date) through Jul 6, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Aug 24, 2020; 11(8): 528-540
Published online Aug 24, 2020. doi: 10.5306/wjco.v11.i8.528

Table 1 Clinical trials investigating venetoclax combination therapy

ClinicalTrials.gov identifier	Treatment combination	Phase	Population
NCT03709758	Venetoclax + daunorubicin + cytarabine	Ib	Untreated
NCT03214562	Venetoclax + fludarabine, cytarabine, filgrastim, idarubicin	Ib/II	Untreated Relapsed/refractory
NCT03471260	Venetoclax + ivosidenib ± azacitidine	I/II	Relapsed/refractory
NCT02993523	Venetoclax + placebo or azacitidine	III	Untreated
NCT03069352	Venetoclax + placebo or low dose cytarabine	III	Untreated
NCT03466294	Venetoclax + azacitidine	II	Untreated-elderly
NCT03404193	Venetoclax + decitabine 10 d	II	Untreated
NCT03586609	Venetoclax + low dose cytarabine+ cladribine + azacitidine	II	Untreated
NCT03236857	Venetoclax ± chemotherapy (various)	I	Relapsed/refractory malignancies (including AML)
NCT03455504	Venetoclax + fludarabine + cytarabine + idarubicin	II	Untreated
NCT03629171	Venetoclax + liposomal daunorubicin -cytarabine	II	Untreated Relapsed/refractory
NCT03862157	Venetoclax + azacitidine + pevonedistat	I/II	Untreated
NCT03390296	Venetoclax + azacitidine + avelumab	I/II	Untreated
NCT03390296	Venetoclax + azacitidine + gemtuzumab ozogamicin + anti-OX40 antibody	I/II	Relapsed/refractory
NCT03867682	Venetoclax + lintuzumab-Ac225	I/II	Relapsed/refractory
NCT03932318	Venetoclax + azacitidine + lintuzumab-Ac225	I/II	Relapsed/refractory
NCT03672695	Venetoclax + S64315	I	Relapsed/refractory
NCT03797261	Venetoclax + AMG-176	Ib	Relapsed/refractory
NCT03063944	Venetoclax + decitabine + OPB-111077	Ib/II	Relapsed/refractory
NCT03484520	Venetoclax + dinaciclib	Ib	Relapsed/refractory
NCT03441555	Venetoclax + alvocidib	Ib	Relapsed/refractory
NCT02670044	Venetoclax + cobimetinib; Venetoclax + idasanutlin	I/II	Relapsed/refractory
NCT03940352	Venetoclax + HDM201	I	Relapsed/refractory
NCT03874052	Venetoclax + ruxolitinib	I	Relapsed/refractory
NCT03471260	Venetoclax + ivosidenib	Ib/II	Relapsed/refractory
NCT04092179	Venetoclax + enasidenib	Ib/II	Relapsed/refractory
NCT03735875	Venetoclax + quizartinib	Ib/II	Relapsed/refractory
NCT03625505	Venetoclax + gilteritinib	I	Relapsed/refractory

AML: Acute myeloid leukemia.

Citation: Wilde L, Ramanathan S, Kasner M. B-cell lymphoma-2 inhibition and resistance in acute myeloid leukemia. World J Clin Oncol 2020; 11(8): 528-540
URL: https://www.wjgnet.com/2218-4333/full/v11/i8/528.htm
DOI: https://dx.doi.org/10.5306/wjco.v11.i8.528